For instance, the use of genetically engineered mAb against DEC-205 receptor has been demonstrated to activate CD4+ and CD8+ T-cells responses and to induce protective immunity against different infectious agents such as Leishmania major (68), Yersinia pestis (69) or viral infections like recombinant vaccinia virus or HIV-1 (70). This evidence concerns the gene CD8A and viral infectious disease.